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patients after MitraClip therapy.
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BACKGROUND Mitral annuloplasty has been shown to be effective for
degenerative and functional mitral regurgitation (MR). However,
incidence of recurrent MR increases over time. We hypothesized that
progressive annuloplasty with implantation of adjustable ring might
not only decrease MR but also restrict further dilatation of the
annulus. This study aimed to evaluate the tissue healing reaction of
an implanted circumferential annuloplasty ring and the feasibility of
progressive cinching of the ring to reduce the diameter of the mitral
annulus in a sheep model.
METHODS The multi-element circumferential ring with eight anchors
(Cardiac Implants, Tarrytown, NY) was implanted to the circumfer-
ence of the mitral annulus near the base of the leaﬂets in 4 sheep via
open-heart procedure under cardiopulmonary bypass (CPB) support.
A mechanical cinching actuator attached to the ring was passed
through the interatrial septum and placed in the superior vena cava.
Cinching mechanism and gross histological evaluations were assessed
90 days post operatively.
RESULTS The ring was successfully anchored on mitral annulus and
the animals recovered from CPB procedures. Follow-up echocardi-
ography after 90 days conﬁrmed devices in the intended position
without interference with mitral valve function. The ring was
cinched using the cinching wire extension and the annular diameters
and area were remarkably decreased (Figure). Histology examination
showed the anchors positioned vertically with completion of tissue
healing response of the rings. All device components were
incorporated within collagenous tissue in-growth except for the
internal cinching wire. No surface thrombi were found around the
cinching actuator.CONCLUSIONS In this ﬁrst feasibility study, surgical implantation of
the circumferential annuloplasty ring was safe and allowed for
chronic progressive cinching following completion of tissue healing
over 90 days. This ring may be an essential component of further
catheter-based therapeutics for mitral valve repair and replacement.
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BACKGROUND The lack of common physiological retention features
as well as the varying and challenging anatomy of the mitral valve
presents a signiﬁcant challenge for the development of transcatheter
mitral valve replacement system. This study aimed to evaluate the
feasibility of acute retention in the mitral position of current com-
mercial transcatheter aortic valves using a novel valve retention sys-
tem (daVingi Ring, Cardiac Implants, Tarrytown, NY) in a pig model.
METHODS The daVingi Ring was delivered below the annular level on
the left ventricle (LV) side of the mitral valve annulus via transapical
access and captured the leaﬂets with small-proﬁle anchors in 4 pigs.
Then, a transcatheter aortic valve was deployed within the daVingi
Ring in the mitral position. The position and function of the implanted
aortic bioprosthetic valve was conﬁrmed by angiography and echo-
cardiography. Animals were euthanized 1 hour after device implan-
tation for gross inspection.
RESULTS The daVingi Ring was successfully deployed below the
annulus of the mitral valve and captured the leaﬂets with the anchors
in all animals (Figure a). The transcatheter aortic valve was
successfully expanded into the ring within the mitral position
(Figure b) without LV outﬂow tract obstruction (Figure c) or
signiﬁcant paravalvular leak (Figure d). Gross examination showed
the implanted valve was deployed halfway through the daVingi Ring
with no damage to the papillary muscles or chordae tendineae.
CONCLUSIONS It is feasible to deploy and maintain a transcatheter
aortic valve in the optimal mitral position following transapical im-
plantation of the daVingi Ring in a pig model. This valve retention
system might provide an easy approach to enable delivery of existing
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mitral valve disease.
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BACKGROUND The REALISM study, the largest US-based study of the
MitraClip Device, is a continued access registry designed for long-term
data collection on the use of MitraClip Device in a “real world” setting.
Retrospective analyses are being performed to determine the proce-
dural learning curve related to the MitraClip procedure.
METHODS A total of 628 high risk and 271 non-high risk patients, with
symptomatic chronic moderate-to-severe (3þ) or severe (4þ) mitral
regurgitation (MR), were enrolled at 38 centers with varying degrees
of experience. Learning curve effects on procedural, safety, and efﬁ-
cacy parameters are of particular interest will be investigated.
RESULTS Initial analyses indicate signiﬁcant reduction in procedure
and device time as sites gain experience with the MitraClip device.
Following initial experience, reduction in procedure, device, and
ﬂuoroscopy time was observed, with continuing trend of further
gradual reduction in time. The effect of learning curve on safety and
efﬁcacy is being analyzed.
CONCLUSIONS Initial analysis demonstrates reduction in procedure
time is achieved as each site gains experience. Further analysis will
determine any changes in efﬁcacy and/or safety outcomes associated
with further experience in this large study cohort.
CATEGORIES STRUCTURAL: Valvular Disease: Mitral
KEYWORDS Learning curve, Mitraclip, Mitral regurgitationTCT-711
Moderately Elevated Mean Mitral Gradient after MitraClip Repair of Mitral
Regurgitation Is Not Associated with Increased Mortality
Richard Cheng,1 Emily Tat,1 Reza Arsanjani,1 Mamoo Nakamura,1
Robert Siegel,1 Moody Makar,2 Saibal Kar1
1Cedars-Sinai Heart Institute, Los Angeles, CA; 2Department of
Anesthesiology, Cedars-Sinai Medical Center, Los Angeles, CA
BACKGROUND Mean mitral gradient (MMG) increases after percuta-
neous edge-to-edge repair of mitral regurgitation (MR). Near complete
reduction of MR has been associated with improved outcomes but
may result in an elevated MMG. However, it is not known whether an
elevated post-procedural MMG is associated with all-cause mortality.
METHODS Patients (pts) who underwent percutaneous repair of MR
between April 2009 and May 2014 with the MitraClip device (Abbott
Vascular, Santa Clara, CA) were included. An elevated gradient was
deﬁned as a MMG 5 mmHg on transthoracic echocardiogram prior to
discharge. Survival was compared between pts with and without an
elevated post-procedural MMG by Log Rank test. Univariate Cox
regression analysis of all-cause mortality was performed for the
predictor variables of post-procedural MMG and change in MMG.
Multivariate logistic regression analysis of predictors for an elevated
post-procedural MMG was performed for normal ejection
fraction 60%, reduction of MR  mild-or-moderate, number of clips
placed, and age.
RESULTS 174 pts were included in the analysis. Mean age at
percutaneous repair was 76.9  12.6 yrs and 40.8% were females.
Post-procedural MMG ranged from 1 to 10 mmHg. An elevated post-
procedural MMG 5 mmHg occurred in 52/174 (29.9%) of pts with an
average MMG of 5.9  1.2 mmHg in this group. MMG was signiﬁcantly
lower in the remaining pts (2.7  0.9 mmHg) p<0.001. Baseline MR
was moderate-to-severe in 36/174 (20.7%) of pts and severe in 138/174
(79.3%) of pts and not different between the groups (p¼1.000).
Number of clips used was 1.5  0.5 (median 2) and not different be-
tween the groups (p¼0.144). Procedural success of reducing MR by 2
or more grades (95.4% of pts) or to less than or equal to mild-or-
moderate (82.8% of pts) was not different between groups p¼0.242
and p¼0.665, respectively. Pts with an elevated post-procedural MMG
had a higher increase in MMG 3.6  1.5 vs. 0.9  1.0 mmHg (p<0.001)
after clipping. Pts with an elevated post-procedural MMG had
improved survival (Log rank p¼0.036). In univariate Cox regression
analysis both post-procedural MMG and change in MMG were asso-
ciated with decreased all-cause mortality hazard ratio 0.839 (95% CI
0.721 – 0.977) p¼0.024 and 0.830 (95% CI 0.711 – 0.969) p¼0.019,
respectively. On multivariate logistic regression analysis pts with
normal ejection fraction 60% had an odds ratio of 2.241 (95% CI 1.125
– 4.461) p¼0.022 for developing an elevated post-procedural MMG.
Reduction of MR to  mild-or-moderate, number of clips, and age
were not signiﬁcantly associated with an elevated post-procedural
MMG.
CONCLUSIONS Moderate elevation of post-procedural MMG is not
associated with increased mortality and may be the expression of
improved hemodynamics. An increase of MMG 3 mmHg to a post-
procedural MMG of 5-10 mmHg might be expected for optimal
outcomes.
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BACKGROUND Right ventricular function is an important determi-
nant of clinical symptoms, exercise capacity, and survival in patients
with Mitral Stenosis. The aim of this study is to evaluate immediate
and mid-term impact of successful percutaneous transvenous mitral
commissurotomy (PTMC) on systolic right ventricular function.
METHODS Twelve patients with severe symptomatic mitral stenosis
who underwent PTMC were included, all patients were subjected to
transthoracic echocardiography assessment of severity of mitral ste-
nosis and right ventricular systolic function before and 24h post-
PTMC then at one and three months.
